FEBRUARY 08, 2012

Browse Categories

Contribute to UroToday

Contribute to UroToday

Be a part of the published community of UroToday and promote awareness among your colleagues.

If you are interested in writing for UroToday Contact Us

editors@urotoday.com

Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board
Urotoday Exclusives

BERKELEY, CA (UroToday.com) - An Optimistic Take on Recent Onset BPS/IC  

Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board
CAUTI Challenge

CAUTI CHALLENGE TODAY (TM) is a part of your Urology Insights newsletter subscription. Access the latest commentary from CAUTI Expert Diane K. Newman, recent publications and experiences from those in the CAUTI treatment community.
Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board
UIJ

UroToday International Journal is a peer-reviewed, online publication featuring many types of articles about clinical urology and basic research in urology.
No Cost
There is no charge to submit, or publish an article in the UroToday International Journal. Additionally, there are no charges for color figures.
.....
Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board

Exclusive Headlines

BJUI Mini Reviews - The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: A meta-analysis with comments on gold standard

BERKELEY, CA (UroToday.com) - The purpose of this review was to examine evidence on the sensitivity of fluorescentlight cystoscopy (FLC; alternative term photodynamic diagnosis) for urothelial carcinoma in situ (CIS) of the bladder, and to offer a discussion from a histopathology

see full text
GU Cancers Symposium 2012 - Prostate cancer: Take home message - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) -

see full text
BJUI Mini Reviews - How to develop a simulation programme in urology

BERKELEY, CA (UroToday.com) - Urology training, like most surgical specialties, has traditionally adopted a volume-based apprenticeship structure to facilitate skill acquisition and ensure competence.[ 1 ]

see full text
GU Cancers Symposium 2012 - Empiric antibiotics for an elevated PSA: A randomized, prospective multiinstitutional trial - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - Researchers from six medical centers investigated the empiric use of the antibiotic (ciprofloxacin 500 mg given twice daily) to treat 77 asymptomatic males with newly elevated PSA (>2.5 ng/ml) undergoing their first prostate biopsy.

see full text

BJU Int Mini Reviews

UroToday News

Unilateral exophthalmos revealing metastatic prostate cancer - Abstract

Prostate cancer, when metastatic, typically involves the axial skeleton.

see full text
Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era - Abstract

OBJECTIVE: To determine long-term oncological outcomes and complication rates for patients with clinically organ confined prostate adenocarcinoma (PCa) treated with open radical retropubic prostatectomy and pelvic lymph node dissection (RRP/PLND) in the prostate-specific antigen

see full text
Understanding variation in primary prostate cancer treatment within the Veterans Health Administration - Abstract

OBJECTIVE: To examine the variation in prostate cancer treatment in the Veterans Health Administration (VHA)-a national, integrated delivery system.

see full text
Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer - Abstract

PURPOSE: Whether race influences bone loss and fracture risk during androgen deprivation therapy for prostate cancer is unknown.

see full text

Share |